CONTACT US
Home > Inhibitors/Agonists>Antibacterials> > Propamidine isethionate
140-63-6-Propamidine isethionate Propamidine isethionate

Propamidine isethionate

For research use only. Not for therapeutic Use.

  • CAT Number: I035056
  • CAS Number: 140-63-6
  • Molecular Formula: C21H32N4O10S2
  • Molecular Weight: 564.625
  • Purity: 98%
Inquiry Now
Related Small Molecules: SX 011     Zampilimab     ICA-121431    

Propamidine isethionate(CAT: I035056) is a biologically active chemical compound. It is an antiseptic and antiprotozoal agent that is used for the treatment of various infections, particularly those caused by certain protozoa. Propamidine isethionate is commonly utilized in ophthalmic preparations to treat eye infections, such as conjunctivitis and keratitis. It works by disrupting the growth and replication of microorganisms, helping to eliminate the infection. Due to its antimicrobial properties, propamidine isethionate finds applications in both medical and veterinary settings for the management of ocular infections.


Catalog Number I035056
CAS Number 140-63-6
Synonyms

Propamidine isethionate

Molecular Formula C21H32N4O10S2
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name Ethanesulfonic acid, 2-hydroxy-, compd. with 4,4'-(trimethylenedioxy)dibenzamidine (2:1)
InChI InChI=1S/C17H20N4O2.2C2H6O4S/c18-16(19)12-2-6-14(7-3-12)22-10-1-11-23-15-8-4-13(5-9-15)17(20)21;2*3-1-2-7(4,5)6/h2-9H,1,10-11H2,(H3,18,19)(H3,20,21);2*3H,1-2H2,(H,4,5,6)
InChIKey WSOSYBUSMXEYDO-UHFFFAOYSA-N
SMILES OCCS(=O)(O)=O.OCCS(=O)(O)=O.N=C(N)C1=CC=C(OCCCOC2=CC=C(C=C2)C(N)=N)C=C1
Reference

1: Lin IH, Tseng SH, Huang FC, Huang YH. Effect of ethanol pretreatment in Acanthamoeba keratitis: a long-term follow-up study. Infect Drug Resist. 2018 Jul 5;11:937-943. doi: 10.2147/IDR.S167775. eCollection 2018. PubMed PMID: 30013376; PubMed Central PMCID: PMC6038874.
2: Dos Santos DL, Kwitko S, Marinho DR, de Araújo BS, Locatelli CI, Rott MB. Acanthamoeba keratitis in Porto Alegre (southern Brazil): 28 cases and risk factors. Parasitol Res. 2018 Mar;117(3):747-750. doi: 10.1007/s00436-017-5745-y. Epub 2018 Jan 14. PubMed PMID: 29332157.
3: Fernández-Ferreiro A, Santiago-Varela M, Gil-Martínez M, González-Barcia M, Luaces-Rodríguez A, Díaz-Tome V, Pardo M, Méndez JB, Piñeiro-Ces A, Rodríguez-Ares MT, Lamas MJ, Otero-Espinar FJ. In Vitro Evaluation of the Ophthalmic Toxicity Profile of Chlorhexidine and Propamidine Isethionate Eye Drops. J Ocul Pharmacol Ther. 2017 Apr;33(3):202-209. doi: 10.1089/jop.2016.0053. PubMed PMID: 28384032.
4: Niyyati M, Dodangeh S, Lorenzo-Morales J. A Review of the Current Research Trends in the Application of Medicinal Plants as a Source for Novel Therapeutic Agents Against Acanthamoeba Infections. Iran J Pharm Res. 2016 Fall;15(4):893-900. PubMed PMID: 28243287; PubMed Central PMCID: PMC5316269.
5: Sengor T, Yuzbasioglu E, Aydın Kurna S, Irkec M, Altun A, Kökcen K, Yalcin NG. Dacryoadenitis and extraocular muscle inflammation associated with contact lens-related Acanthamoeba keratitis: A case report and review of the literature. Orbit. 2017 Feb;36(1):43-47. doi: 10.1080/01676830.2016.1243132. Epub 2016 Nov 22. Review. PubMed PMID: 27874294.
6: Kwok PW, Kam KW, Jhanji V, Young AL. Painless Acanthamoeba Keratitis with Normal Vision. Optom Vis Sci. 2017 Mar;94(3):432-435. doi: 10.1097/OPX.0000000000001023. PubMed PMID: 27870779.
7: Reichart-Peter S, Manousaridis K, Dirschmid H, Mennel S. [Good outcome in Acanthamoeba keratitis]. Ophthalmologe. 2017 Jul;114(7):653-655. doi: 10.1007/s00347-016-0350-5. German. PubMed PMID: 27558689.
8: Carnt N, Robaei D, Watson SL, Minassian DC, Dart JK. The Impact of Topical Corticosteroids Used in Conjunction with Antiamoebic Therapy on the Outcome of Acanthamoeba Keratitis. Ophthalmology. 2016 May;123(5):984-90. doi: 10.1016/j.ophtha.2016.01.020. Epub 2016 Mar 5. PubMed PMID: 26952591.
9: Sarnicola E, Sarnicola C, Sabatino F, Tosi GM, Perri P, Sarnicola V. Early Deep Anterior Lamellar Keratoplasty (DALK) for Acanthamoeba Keratitis Poorly Responsive to Medical Treatment. Cornea. 2016 Jan;35(1):1-5. doi: 10.1097/ICO.0000000000000681. PubMed PMID: 26562819.
10: Sunada A, Kimura K, Nishi I, Toyokawa M, Ueda A, Sakata T, Suzuki T, Inoue Y, Ohashi Y, Asari S, Iwatani Y. In vitro evaluations of topical agents to treat Acanthamoeba keratitis. Ophthalmology. 2014 Oct;121(10):2059-65. doi: 10.1016/j.ophtha.2014.04.013. Epub 2014 May 29. PubMed PMID: 24880905.
11: Siddiqui R, Chaudhry T, Lakhundi S, Ahmad K, Khan NA. Failure of chemotherapy in the first reported cases of Acanthamoeba keratitis in Pakistan. Pathog Glob Health. 2014 Jan;108(1):49-52. doi: 10.1179/2047773213Y.0000000124. Epub 2013 Dec 27. PubMed PMID: 24548160; PubMed Central PMCID: PMC4083167.
12: Patel DV, McGhee CNj. Presumed late recurrence of Acanthamoeba keratitis exacerbated by exposure to topical corticosteroids. Oman J Ophthalmol. 2013 Sep;6(Suppl 1):S40-2. doi: 10.4103/0974-620X.122295. PubMed PMID: 24391372; PubMed Central PMCID: PMC3872843.
13: Szentmáry N, Daas L, Matoula P, Goebels S, Seitz B. [Acanthamoeba keratitis]. Ophthalmologe. 2013 Dec;110(12):1203-10; quiz 1211. doi: 10.1007/s00347-013-2981-0. German. PubMed PMID: 24337209.
14: Erdem E, Evcil Y, Yagmur M, Eroglu F, Koltas S, Ersoz R. Non-contact lens use-related Acanthamoeba keratitis in southern Turkey: evaluation of risk factors and clinical features. Eur J Ophthalmol. 2014 Mar-Apr;24(2):164-72. doi: 10.5301/ejo.5000357. Epub 2013 Sep 5. PubMed PMID: 24030538.
15: Polat ZA, Walochnik J, Obwaller A, Vural A, Dursun A, Arici MK. Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis. Clin Exp Ophthalmol. 2014 Mar;42(2):151-8. doi: 10.1111/ceo.12120. Epub 2013 May 21. PubMed PMID: 23601234.
16: Behrens-Baumann W, Seibold M, Hofmüller W, Walter S, Haeberle H, Wecke T, Tammer I, Tintelnot K. Benefit of polyhexamethylene biguanide in Fusarium keratitis. Ophthalmic Res. 2012;48(4):171-6. doi: 10.1159/000337140. Epub 2012 Jun 16. PubMed PMID: 22710976.
17: Yamazoe K, Yamamoto Y, Shimazaki-Den S, Shimazaki J. Visual outcome in Japanese patients with Acanthamoeba keratitis. Eye (Lond). 2012 Apr;26(4):517-22. doi: 10.1038/eye.2011.366. Epub 2012 Jan 13. PubMed PMID: 22241017; PubMed Central PMCID: PMC3325582.
18: Li ML, Shih MH, Huang FC, Tseng SH, Chen CC. Treatment of early Acanthamoeba keratitis with alcohol-assisted epithelial debridement. Cornea. 2012 Apr;31(4):442-6. doi: 10.1097/ICO.0b013e31823f091a. PubMed PMID: 22236786.
19: Moreno-Montañés J, Barrio-Barrio J, De-Nova E, Werner L. Lens epithelial cell death secondary to acanthamoeba keratitis: absence of capsular bag opacification six years after cataract surgery. Case Rep Ophthalmol. 2011 Sep;2(3):354-9. doi: 10.1159/000334785. Epub 2011 Dec 2. PubMed PMID: 22220159; PubMed Central PMCID: PMC3250659.
20: Kashiwabuchi RT, Carvalho FR, Khan YA, de Freitas D, Foronda AS, Hirai FE, Campos MS, McDonnell PJ. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites. Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9333-8. doi: 10.1167/iovs.11-8382. PubMed PMID: 22058341.

Request a Quote